“…Furthermore, in the absence of genetic drift (Box 1), drug‐resistant mutations with low or no biological cost are more likely to be selected and maintained in the populations (Farhat et al., 2013; Osorio et al., 2013). For instance, the predominant mutations associated with high level of drug resistance and a low or no biological cost, such as kat G S315T, rpo B S531L, rps L K43R and gyr A D94G (conferring resistance to isoniazid, rifampicin, streptomycin and fluoroquinolones respectively), are more frequently found in clinical drug‐resistant isolates (Billington et al., 1999; Bottger et al., 1998; Campbell et al., 2011; Casali et al., 2014; Gagneux, Burgos, et al., 2006; Gagneux, Long, et al., 2006; Mariam et al., 2004; Pym et al., 2002). Indeed, some of these resistance mutations do not reduce bacterial fitness in the absence of treatment (Bergval, Schuitema, Klatser, & Anthony, 2009; Huitric et al., 2006; Mariam et al., 2004).…”